filmov
tv
Tumore del polmone KRAS G12C, dati importanti su sotorasib
Показать описание
OncoInfoTV
oncologia
oncoinfo
Рекомендации по теме
0:03:25
Tumore del polmone KRAS G12C, dati importanti su sotorasib
0:05:17
Tumore del polmone, arriva in Italia sotorasib, primo agente orale mirato contro mutazione KRAS G12C
0:05:54
Tumore del polmone, via libera europeo per sotorasib, primo anti-KRAS
0:07:44
Tumore del polmone avanzato, ok Aifa a sotorasib per i pazienti con la mutazione KRAS G12C
0:01:42
Treating KRAS G12C Mutations
0:08:14
Parliamo della mutazione KRASg12
0:05:38
Profilazione molecolare del tumore del polmone: il ruolo della mutazione KRAS p.G12C
0:07:44
Treatment for KRAS G12C Mutated NSCLC with High Tumor Mutational Burden -Case-Based Panel Discussion
0:02:09
ESMO highlights: KRAS G12C inhibitors
0:01:10
Targeting non-G12C KRAS mutations in NSCLC
0:01:59
Molecular determinants of KRAS G12C inhibitor efficacy in advanced NSCLC
0:00:50
KRAS G12C Emerges as New Potential Target in Non-Small Cell Lung Cancer
0:05:26
ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C Mutation
0:07:51
KRAS G12C Inhibition in Advanced NSCLC: AMG 510
0:03:17
Mechanisms of resistance to KRAS G12C inhibitors
0:02:24
Tumore del polmone: come cambiano prima, seconda e terza linea
0:01:12
Overcoming resistance to KRAS G12C inhibitors in NSCLC
0:02:38
Key lung cancer updates: KRAS(G12C) inhibitors and ADCs
0:01:37
Expert Discusses KRAS G12C Inhibitors for Patients with NSCLC
0:01:10
Current treatment strategies KRASG12C–mutated NSCLC
0:05:14
Real-world outcomes by co-mutation status in KRAS G12C-mutant NSCLC
0:01:26
KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer
0:05:23
KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies
0:05:29
Development of KRAS G12C-Targeted Therapy in NSCLC
0:03:25
0:05:17
0:05:54
0:07:44
0:01:42
0:08:14
0:05:38
0:07:44
0:02:09
0:01:10
0:01:59
0:00:50
0:05:26
0:07:51
0:03:17
0:02:24
0:01:12
0:02:38
0:01:37
0:01:10
0:05:14
0:01:26
0:05:23
0:05:29